NICE Backs Tryngolza for FCS, Giving Sobi a Monthly Successor to Its Own Waylivra
Sobi is moving its FCS franchise to a less frequent, better-tolerated drug, on broader NICE terms than the one it replaces.
NeuroPulse
DealPulse Signal
The Beats
Analysis
The Briefs
NICE Backs Tryngolza for FCS, Giving Sobi a Monthly Successor to Its Own Waylivra
Pharmac Will Fund Any Medicine for Young People With Paediatric-Origin Cancers, About 15 a Year
Korea Now Reimburses BeOne’s Tevimbra First-Line in Three Cancers, Using PD-L1 Cutoffs to Set the Limits
Sanofi Pays Regeneron $1 Billion to Keep Dupixent’s Successors Inside a 23-Year Alliance
Medicare Advantage Premiums Fall 16.5% for 2027 While Part D Deductibles Rise 30%